ClinConnect ClinConnect Logo
Search / Trial NCT06620341

A Cluster Randomized Controlled Trial to Compare the Rate of Antibiotic Infusion

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Sep 29, 2024

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

Bacterial Infection Of Upper Respiratory Tract Infusion Rate Pharmacist

ClinConnect Summary

This clinical trial is looking at how to reduce the use of intravenous antibiotics for patients with bacterial infections of the upper respiratory tract, like colds or sore throats, who come to the emergency room. It aims to see if education from clinical pharmacists can help doctors use these antibiotics more wisely, which could lower costs for patients and decrease the risk of side effects and antibiotic resistance. The study will observe whether this approach affects patient recovery and safety while ensuring they still get the right treatment.

To participate in this trial, you need to be at least 18 years old and visiting the emergency room for an upper respiratory tract infection that shows signs of needing antibiotics, like a high white blood cell count or specific symptoms such as fever or cough. However, if you have other infections, are severely ill, or have certain health conditions, you won't be eligible. Participants can expect to engage in educational sessions about medication use and will be closely monitored to see how these changes impact their treatment and health outcomes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with upper respiratory tract infections seeking emergency medical attention;
  • Patients with laboratory tests indicating White Blood Cell (WBC) \>10×10\^9/L or White Blood Cell (CRP) ≥ 10.0mg/L, requiring the use of antimicrobial agents;
  • Patients aged ≥ 18 years; ④ Patients with at least one of the following local signs and symptoms: (1) fever, (2) cough, (3) rhinitis (sneezing, nasal congestion, or rhinorrhea), (4) pharyngitis (sore throat), (5) shortness of breath, (6) wheezing, (7) chest pain, (8) abnormal auscultation findings.
  • Exclusion Criteria:
  • Patients with other infections in addition to upper respiratory tract infections; ② Patients who require hospitalization or treatment in a higher-level medical institution as assessed by medical professionals;
  • Patients who cannot take oral medications or have severe gastrointestinal dysfunction; ④ Special patients, including those with neutropenia, bone marrow suppression, during radiochemotherapy, undergoing immunosuppressive therapy, human immunodeficiency virus (HIV)-positive patients, patients with congenital immune deficiency, pregnant patients, and patients with mental illnesses.

About Second Affiliated Hospital, School Of Medicine, Zhejiang University

The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.

Locations

Hangzhou, Zhejiang, China

Patients applied

0 patients applied

Trial Officials

Haibin Dai, Professor

Principal Investigator

Second Affiliated Hospital, School of Medicine, Zhejiang University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported